A closer look at endothelial injury-induced platelet hyperactivity and the use of aspirin in the treatment of COVID infection

In this commentary, we make a case that the mechanism of COVID pathogenesis is related to virus-induced endothelial injury resulting in platelet activation and the formation of microthrombi both systemically and in cardiac and pulmnonary circulation which result in major causes of COVID morbidity an...

Descripción completa

Detalles Bibliográficos
Autores principales: Lichtenberger, Lenard M., Szabo, Sandor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9213171/
https://www.ncbi.nlm.nih.gov/pubmed/35729443
http://dx.doi.org/10.1007/s10787-022-01015-w
_version_ 1784730780192210944
author Lichtenberger, Lenard M.
Szabo, Sandor
author_facet Lichtenberger, Lenard M.
Szabo, Sandor
author_sort Lichtenberger, Lenard M.
collection PubMed
description In this commentary, we make a case that the mechanism of COVID pathogenesis is related to virus-induced endothelial injury resulting in platelet activation and the formation of microthrombi both systemically and in cardiac and pulmnonary circulation which result in major causes of COVID morbidity and mortality. Aspirin by virtue of its irreversible inhibition of platelet COX-1, should reverse these platelet-induced pathogenic changes associated with COVID infection for the 6–9 day lifetime of the platelet. We also cite recent findings of a retrospective analysis that supports the use of low-dose (81 mg) aspirin to treat the symptoms associated with the early stages of COVID infection.
format Online
Article
Text
id pubmed-9213171
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-92131712022-06-22 A closer look at endothelial injury-induced platelet hyperactivity and the use of aspirin in the treatment of COVID infection Lichtenberger, Lenard M. Szabo, Sandor Inflammopharmacology Commentary In this commentary, we make a case that the mechanism of COVID pathogenesis is related to virus-induced endothelial injury resulting in platelet activation and the formation of microthrombi both systemically and in cardiac and pulmnonary circulation which result in major causes of COVID morbidity and mortality. Aspirin by virtue of its irreversible inhibition of platelet COX-1, should reverse these platelet-induced pathogenic changes associated with COVID infection for the 6–9 day lifetime of the platelet. We also cite recent findings of a retrospective analysis that supports the use of low-dose (81 mg) aspirin to treat the symptoms associated with the early stages of COVID infection. Springer International Publishing 2022-06-22 2022 /pmc/articles/PMC9213171/ /pubmed/35729443 http://dx.doi.org/10.1007/s10787-022-01015-w Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Commentary
Lichtenberger, Lenard M.
Szabo, Sandor
A closer look at endothelial injury-induced platelet hyperactivity and the use of aspirin in the treatment of COVID infection
title A closer look at endothelial injury-induced platelet hyperactivity and the use of aspirin in the treatment of COVID infection
title_full A closer look at endothelial injury-induced platelet hyperactivity and the use of aspirin in the treatment of COVID infection
title_fullStr A closer look at endothelial injury-induced platelet hyperactivity and the use of aspirin in the treatment of COVID infection
title_full_unstemmed A closer look at endothelial injury-induced platelet hyperactivity and the use of aspirin in the treatment of COVID infection
title_short A closer look at endothelial injury-induced platelet hyperactivity and the use of aspirin in the treatment of COVID infection
title_sort closer look at endothelial injury-induced platelet hyperactivity and the use of aspirin in the treatment of covid infection
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9213171/
https://www.ncbi.nlm.nih.gov/pubmed/35729443
http://dx.doi.org/10.1007/s10787-022-01015-w
work_keys_str_mv AT lichtenbergerlenardm acloserlookatendothelialinjuryinducedplatelethyperactivityandtheuseofaspirininthetreatmentofcovidinfection
AT szabosandor acloserlookatendothelialinjuryinducedplatelethyperactivityandtheuseofaspirininthetreatmentofcovidinfection
AT lichtenbergerlenardm closerlookatendothelialinjuryinducedplatelethyperactivityandtheuseofaspirininthetreatmentofcovidinfection
AT szabosandor closerlookatendothelialinjuryinducedplatelethyperactivityandtheuseofaspirininthetreatmentofcovidinfection

Ejemplares similares